Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Gastric cancer (GC) is one of the most malignant human cancers with increasing incidence
worldwide, ranking among the top five malignant tumors worldwide in terms of incidence …

As one of the most common forms of solid tumours, gastric carcinoma has been revealed as
the third leading cause of death worldwide. The symptom of gastric cancer is usually not …

Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery
and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) …

Background Emerging evidence supports combining immune checkpoint inhibitors (ICIs)
with conventional or targeted therapies to enhance ICI antitumour activity and broaden the …

Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for
various cancer types. Multiple single or combinations of ICB treatments have been approved …

In this era of precision medicine, with the help of biomarkers, immunotherapy has
significantly improved prognosis of many patients with malignant tumor. Deficient mismatch …

Background Targeting the DNA damage repair (DDR) pathways is an attractive strategy for
boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral kinase inhibitor of ataxia …

Mitochondria are biosynthetic, bioenergetic, and signaling organelles existing in almost all
eukaryotic cells, and their dysregulated function has been proved to be essential for …

Several targeted therapies have shown efficacy in patients with advanced gastric cancer
(GC) and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic …